TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02054065

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAUTI Decision Support
Description: Decision support used to prevent Catheter Associated Urinary Tract Infections
Study: NCT02607124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Study: NCT01985334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAMA
Description: Long Acting Muscarinic Antagonist (LAMA) as per approved by each country and as prescribed for each patient, used as background therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAMA
Description: Long Acting Muscarinic Antagonist (LAMA) as per approved by each country and as prescribed for each patient, used as background therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAMA
Description: Long Acting Muscarinic Antagonist (LAMA) as per approved by each country and as prescribed for each patient, used as background therapy
Study: NCT02881983

Intervention type: OTHER
Intervention: the presentation of pictures (static stimuli) or videos (dynamic stimuli)
Study: NCT01985334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAMA
Description: Long Acting Muscarinic Antagonist (LAMA) as per approved by each country and as prescribed for each patient, used as background therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAMA
Description: Short-acting muscarinic antagonist (SAMA) as per approved by each country and as prescribed for each patient, used as background therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAMA
Description: Short-acting muscarinic antagonist (SAMA) as per approved by each country and as prescribed for each patient, used as background therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICS
Description: Inhaled corticosteroid (ICS) as per approved by each country and as prescribed for each patient, used as background therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICS
Description: Inhaled corticosteroid (ICS) as per approved by each country and as prescribed for each patient, used as background therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICS
Description: Inhaled corticosteroid (ICS) as per approved by each country and as prescribed for each patient, used as background therapy
Study: NCT00243503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU011248/Trastuzumab
Description: SU011248 will be administered orally, starting dose of 37.5 mg daily on a continuous regimen. Trastuzumab will be administered weekly (loading dose 4 mg/kg followed by weekly 2mg/kg) or every 3 weeks (loading dose 8 mg/kg followed by 6mg/kg q3w). Study treatment should continue until progression, withdrawal for other reasons, or for up to 18 months following which patients requiring continued access will be offered SU011248 on a separate protocol.
Study: NCT01546753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Walnut Protein Powder
Description: Blinded study product dosing begins with a 1-day oral desensitization protocol to walnut for subjects in the active arm. Starting at 0.1 mg protein and increasing to a maximum of 6 mg or until allergic symptoms develop. Subjects continue daily dosing of blinded OIT (walnut) with build-up every 2 weeks to a maximum daily dose of 1500mg at week 34, followed by 4 weeks of daily maintenance dosing. OFC to walnut and second tree nut occurs at week 38 then treatment is unblinded and open-label maintenance dosing occurs.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oat Powder (placebo)
Description: Blinded study product dosing begins with a one-day oral desensitization protocol with placebo (oat) powder. Subjects in the placebo group will undergo the same protocol as those in the active group with placebo OIT dosing. Unblinding to treatment assignment will occur after the 38 week oral food challenge. Placebo subjects will cross-over to active, open-label treatment with walnut powder after the 38 week oral food challenge. beginning with initial escalation day, through build-up and maintenance dosing per the same protocol sequence as noted for active, walnut powder. Subjects will complete an oral food challenge to walnut and the second tree nut at week 38 then will continue on long-term, open-label maintenance dosing until the end of study using same protocol design.

Intervention type: DRUG
Group type: OTHER
Intervention: Open-label Walnut Protein Powder
Description: Open-label treatment phase begins after the 38 week oral food challenge with unblinding of treatment assignment. For those on active treatment, daily maintenance dosing occurs for up to a total of 298 weeks. For those on placebo treatment, cross-over to active, open-label treatment occurs using the same active treatment protocol. Placebo-crossover subjects will complete an oral food challenge to walnut and the second tree nut at week 38 of active therapy then continue on long-term, open-label maintenance dosing until the end of study using same protocol design. All subjects may reach a qualifying IgE to walnut/second tree nut early and will undergo an OFCs on and 4 weeks off OIT. All subjects will have OFCs on and 4 weeks off OIT at week 142 and at week 298, unless both walnut/second tree nut OFCs are passed at previous OFC prompting addition of these foods into the diet.
Study: NCT01664247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Administered s.c. (under the skin) once daily. Dose individually adjusted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Administered s.c. (under the skin) once daily. Dose individually adjusted.
Study: NCT02652806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG-4592

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Alfa
Study: NCT03576833

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elipse Balloon system
Description: intragastic balloon
Study: NCT01040754

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: This study follows a standardized acupuncture protocol for OA knee pain. Approximately 6 acupuncture needles are placed in the skin of the leg for 25 minutes.
Study: NCT01770899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gelatin capsule given every 24 hours
Study: NCT01184846

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10% liquid formulation of human immunoglobulin
Study: NCT04372043

Intervention type: OTHER
Intervention: Questionnaire
Description: Sleep Hygiene Index and demographic questions.
Study: NCT04225884

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DTx for pain software
Description: Software with active intervention

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control software
Description: Software without active intervention

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Pain medication
Study: NCT02151682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol prolonged release

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol prolonged release

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine prolonged release
Study: NCT02666508

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plaque identifying toothpaste
Description: Plaque identifying toothpaste with targetol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-plaque identifying toothpaste
Description: Non-plaque identifying toothpaste without targetol
Study: NCT02533193

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERAS perioperative cares
Description: 1. Patient's preoperative counseling \& education before surgery~2. No Bowel preparation~3. Drug: Oral Carbohydrate Solution (OCS). Take 250ml OCS orally 2 hours before surgery~4. Fluid restriction \& Management by pulse contour analysis or transesophageal doppler~5. Early mobilization~6. Early oral feeding (postoperative 1 day - liquid diet, 2 days - semifluid diet (SFD), 3 days - normal diet)~7. Intravenous patient controlled analgesics (no opioids analgesics)~8. Postoperative Nausea Active Control~9. No nasogastric tube~10. No drain insertion~11. Patients will be discharged at POD#4 if there's no problem

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional perioperative cares
Description: 1. No Patient's preoperative counseling \& education before surgery~2. Bowel preparation~3. No Oral Carbohydrate Solution (OCS) loading until 2hours before surgery~4. Conventional Fluid Management by clinical signs (Urine output, heart rate etc.)~5. Conventional Mobilization~6. Conventional oral feeding (POD#2 SOW, #3 SFD, #4 SBD)~7. IV PCA~8. Postoperative Nausea Control if needed~9. No Thromboembolism prophylaxis~10. No or Low Content Oxygen therapy~11. Drainage tube insertion if needed
Study: NCT02420301

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tuina exercises

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tuina exercises
Study: NCT01664247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Administered s.c. (under the skin) once daily. Dose: 1.8 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Administered s.c. (under the skin) once daily. Dose: 1.8 mg.
Study: NCT01541501

Intervention type: DEVICE
Intervention: Pachymetry
Description: Healthy volunteers recruited among subject that underwent a routine ophthalmologic evaluation or among both students and workers at our clinic, will be submitted to CCT measurement through four different instruments: Scheimpflug camera tomography, SD-OCT, anterior chamber SD-OCT, and finally with US pachymeter.
Study: NCT03947567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Coagulation FVIII
Description: Participants received SCT800 for prophylaxis and/or on-demand treatment for 120 weeks.
Study: NCT04378699

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMR (12-15 Hz)
Description: SMR training sessions (12-15 Hz) C4 unipolar placement, central region

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: alpha band (8 -12Hz)
Description: 3 x 10 training sessions of the higher frequencies of the alpha band (8 -12Hz), unipolar placement Fz, fronto-central region
Study: NCT03217201

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light Glasses (Experimental)
Description: The light glasses emit light from LEDs at a distance of 15 millimeters (15mm, 0.015.) from the eye. The device Is classified as safe for the eyes in accordance with the international standard IEC 62471 and complies with the United States of America's FCC marking, and is designed to be worn on the participant's head, similarly to a pair of glasses. For safety purposes, the light glasses do not contain UV or infra-red light.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light Glasses (Experimental)
Description: The light glasses emit light from LEDs at a distance of 15 millimeters (15mm, 0.015.) from the eye. The device Is classified as safe for the eyes in accordance with the international standard IEC 62471 and complies with the United States of America's FCC marking, and is designed to be worn on the participant's head, similarly to a pair of glasses. For safety purposes, the light glasses do not contain UV or infra-red light.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Light Glasses (Comparison)
Description: The light glasses emit light from LEDs at a distance of 15 millimeters (15mm, 0.015.) from the eye. The device Is classified as safe for the eyes in accordance with the international standard IEC 62471 and complies with the United States of America's FCC marking, and is designed to be worn on the participant's head, similarly to a pair of glasses. For safety purposes, the light glasses do not contain UV or infra-red light.
Study: NCT00742521

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: glucose clamp
Description: Day 1 hyperinsulinemic euglycemic glucose clamp procedure x 2 and Day 2 hyperinsulinemic hypoglycemic glucose clamp procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: glucose clamp
Description: Hypoglycemic glucose clamp procedure x 2 on Day 1 and hypoglycemic glucose clamp procedure on Day 2. Control study
Study: NCT03217201

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Light Glasses (Comparison)
Description: The light glasses emit light from LEDs at a distance of 15 millimeters (15mm, 0.015.) from the eye. The device Is classified as safe for the eyes in accordance with the international standard IEC 62471 and complies with the United States of America's FCC marking, and is designed to be worn on the participant's head, similarly to a pair of glasses. For safety purposes, the light glasses do not contain UV or infra-red light.
Study: NCT01306032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-888
Description: PARP enzymes are critical for maintaining genomic stability by regulating a variety of DNA repair mechanisms. Individuals with deleterious mutations in the BRCA1 or BRCA2 tumor suppressor genes have an increased risk of developing breast and ovarian cancers due to impaired or defective DNA damage repair; these individuals have an increased susceptibility to DNA-damaging agents and PARP inhibitors. Inhibition of PARP inhibits the repair of DNA damage caused by alkylating agents such as cyclophosphamide. Metronomic cyclophosphamide has demonstrated efficacy in several tumor types. The PARP inhibitor ABT-888 has been shown to potentiate the action of cyclophosphamide in xenograft models. This combination is well tolerated in a Phase I study and showing promising activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-888
Description: PARP enzymes are critical for maintaining genomic stability by regulating a variety of DNA repair mechanisms. Individuals with deleterious mutations in the BRCA1 or BRCA2 tumor suppressor genes have an increased risk of developing breast and ovarian cancers due to impaired or defective DNA damage repair; these individuals have an increased susceptibility to DNA-damaging agents and PARP inhibitors. Inhibition of PARP inhibits the repair of DNA damage caused by alkylating agents such as cyclophosphamide. Metronomic cyclophosphamide has demonstrated efficacy in several tumor types. The PARP inhibitor ABT-888 has been shown to potentiate the action of cyclophosphamide in xenograft models. This combination is well tolerated in a Phase I study and showing promising activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-888
Description: PARP enzymes are critical for maintaining genomic stability by regulating a variety of DNA repair mechanisms. Individuals with deleterious mutations in the BRCA1 or BRCA2 tumor suppressor genes have an increased risk of developing breast and ovarian cancers due to impaired or defective DNA damage repair; these individuals have an increased susceptibility to DNA-damaging agents and PARP inhibitors. Inhibition of PARP inhibits the repair of DNA damage caused by alkylating agents such as cyclophosphamide. Metronomic cyclophosphamide has demonstrated efficacy in several tumor types. The PARP inhibitor ABT-888 has been shown to potentiate the action of cyclophosphamide in xenograft models. This combination is well tolerated in a Phase I study and showing promising activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study: NCT03683524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG) plus Darunavir/cobicistat (DRV/cobi).
Description: bitherapy based on DTG (50 mg QD) plus DRV/cobi (800/150 mg QD)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Current ART
Description: To continue with their current ART
Study: NCT01306032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study: NCT04314414

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRC brief motivational interview intervention
Description: The intervention will involve the following elements: establishing rapport, asking permission to discuss drugs, discussing the pros and cons associated with drug use, uncovering the gaps between current and desired quality of life and determining readiness to change. The intervention will last approximately 20 minutes and take place at the time of the clinical visit while participants are waiting to be seen by a clinician or are awaiting laboratory testing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone contact
Description: The PRC will remain in at least weekly contact by phone with each participant.
Study: NCT01367652

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: 2.5 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: 2.5 mg Tablet
Study: NCT04279366

Intervention type: BEHAVIORAL
Intervention: Lifestyle intervention
Description: The 14 week courses takes place at a Danish folk high school (Ubberup), specialized in lifestyle interventions targeting a 10% weight loss. Adult individuals with obesity sign up for the course. They stay at the School for the whole course period and the total cost amounts to 300-400 Euros per week plus loss of income.
Study: NCT01306032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study: NCT03049995

Intervention type: PROCEDURE
Intervention: Left ventricular contractile reserve SE
Description: Stress protocols (either physical or pharmacological) will be performed according to recent guidelines recommendations (1,2,3). with special focus on Wall Motion Score Index.

Intervention type: PROCEDURE
Intervention: Left ventricular contractile reserve SE
Description: Stress protocols (either physical or pharmacological) will be performed according to recent guidelines recommendations (1,2,3). with special focus on Wall Motion Score Index.

Intervention type: PROCEDURE
Intervention: Left ventricular contractile reserve SE
Description: Stress protocols (either physical or pharmacological) will be performed according to recent guidelines recommendations (1,2,3). with special focus on Wall Motion Score Index.

Intervention type: PROCEDURE
Intervention: B-lines SE
Description: SE will be performed with special focus on lung sonography and B-lines score (3,4).B-lines will be scored with the 28-regions antero-lateral chest assessment as previously described at baseline and immediately after stopping exercise. A simplified 8-region scan is also allowed in order to save time without loss of critical information.

Intervention type: PROCEDURE
Intervention: B-lines SE
Description: SE will be performed with special focus on lung sonography and B-lines score (3,4).B-lines will be scored with the 28-regions antero-lateral chest assessment as previously described at baseline and immediately after stopping exercise. A simplified 8-region scan is also allowed in order to save time without loss of critical information.

Intervention type: PROCEDURE
Intervention: B-lines SE
Description: SE will be performed with special focus on lung sonography and B-lines score (3,4).B-lines will be scored with the 28-regions antero-lateral chest assessment as previously described at baseline and immediately after stopping exercise. A simplified 8-region scan is also allowed in order to save time without loss of critical information.

Intervention type: PROCEDURE
Intervention: B-lines SE
Description: SE will be performed with special focus on lung sonography and B-lines score (3,4).B-lines will be scored with the 28-regions antero-lateral chest assessment as previously described at baseline and immediately after stopping exercise. A simplified 8-region scan is also allowed in order to save time without loss of critical information.

Intervention type: PROCEDURE
Intervention: Left ventricular outflow tract gradient SE
Description: SE will be performed with special focus on left ventricular outflow tract obstruction (3,4).

Intervention type: PROCEDURE
Intervention: Left ventricular outflow tract gradient SE
Description: SE will be performed with special focus on left ventricular outflow tract obstruction (3,4).
Study: NCT03025490

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capnographic monitoring
Description: Capnographic monitoring is used during the sedation.
Study: NCT02397642

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF/ICSI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF/ICSI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Chorionic Gonadotropin
Description: given in different doses and timing to support the luteal phase

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Chorionic Gonadotropin
Description: given in different doses and timing to support the luteal phase
Study: NCT00093015

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Volume and dose frequency changes resembling dosing in the active treatment group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: darbepoetin alfa
Description: Starting dose : 0.75 mcg/kg subcutaneous (SC) every two weeks (Q2W); subsequent doses titrated to achieve hemoglobin (Hb) target of 13.0 g/dL
Study: NCT00520546

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-Ethylcholine Positron Emission Tomography (FEC-PET)
Description: PET scans were performed on a LSO scanner (ECAT ACCEL, Siemens, Erlangen, Germany) by using a multiphase protocol starting with a cold transmission scan of the lower pelvis. This was followed by a list mode emission scan with 10 frames à 1 minute starting immediately after the administration of 3.3MBq \[18F\]Fluoroethylcholine chloride (FEC; Eckert \& Ziegler EURO-PET Berlin GmbH) as a bolus through the cubital vein. After a short gap due to computer processing time the whole body scan was performed starting at the upper thoracic aperture down to the proximal femur. Acquisition parameters were 3 minutes emission scan and 2 minutes transmission scan for each bed position. Therefore the prostate region was scanned again at 45 minutes p.i. (post injection) A delayed local acquisition at 65 minutes over the lower pelvis with 6 minutes emission and 2 minutes transmission finished the diagnostic acquisition procedure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endorectal Magnetic Resonance Imaging (1.5Tesla) (eMRI)
Description: The MRI examination was performed on a 1.5Tesla MRI system (Gyroscan ACS-NT, Philips, Hamburg, Germany) with combined QBody and endorectal coil. Pelvic assessment and lymph node staging was effected with 5mm T2 weighted (T2w) turbo spin echo (TSE) transversal and a coronal short-tau inversion recovery (STIR) sequence. For prostate assessment, 3mm endorectal T2w spin echo (SE) sagittal, transversal and coronal sequences were acquired.
Study: NCT03348371

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: The intervention is two different administrationforms of ethanol, orally and i.v.